Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 13c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.93, $0.13 better than the analyst estimate of $0.80. Revenue for the quarter came in at $48.1 million versus the consensus estimate of $45.86 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• B.Riley Assumes Anika Therapeutics (ANIK) at Buy
• Corpay agrees to $100M FTC settlement over marketing practices